Current acute stroke trials and their potential impact on the therapeutic time window

References

• Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med.359(13), 1317–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke40(7), 2594–2600 (2009).
   PubMed Web of Science ®Google Scholar
• Vahedi K, Hofmeijer J, Juettler E et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol.6(3), 215–222 (2007).
   PubMed Web of Science ®Google Scholar
• Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet363(9411), 768–774 (2004).
   PubMed Web of Science ®Google Scholar
• Lees KR, Bluhmki E, von Kummer R et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet375(9727), 1695–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Heuschmann PU, Berger K, Misselwitz B et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke34(5), 1106–1113 (2003).
   PubMed Web of Science ®Google Scholar
• Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA283(9), 1151–1158 (2000).
   PubMed Web of Science ®Google Scholar
• Wintermark M, Albers GW, Alexandrov AV et al. Acute stroke imaging research roadmap. Stroke29(5), e23–e30 (2008).
   Google Scholar
• Schellinger PD. The evolving role of advanced MR imaging as a management tool for adult ischemic stroke: a Western-European perspective. Neuroimaging Clin. N. Am.15(2), 245–258, ix (2005).
   PubMedGoogle Scholar
• Schellinger PD, Thomalla G, Fiehler J et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke38(10), 2640–2645 (2007).
   PubMed Web of Science ®Google Scholar
• Kohrmann M, Schellinger PD, Schwab S. The only evidence based neuroprotective therapy for acute ischemic stroke: thrombolysis. Best practice and research. Clin. Anaesthesiol.24(4), 563–571 (2010).
   Google Scholar
• Schellinger PD, Bryan RN, Caplan LR et al. Evidence-based guideline: the role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology75(2), 177–185 (2010).
   PubMed Web of Science ®Google Scholar
• Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke34(11), 2729–2735 (2003).
   PubMed Web of Science ®Google Scholar
• Chalela JA, Kang DW, Luby M et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. Ann. Neurol.55(1), 105–112 (2004).
   PubMedGoogle Scholar
• Schellinger PD, Fiebach JB, Jansen O et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann. Neurol.49(4), 460–469 (2001).
   PubMed Web of Science ®Google Scholar
• Schlaug G, Benfield A, Baird AE et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology53(7), 1528–1537 (1999).
   PubMed Web of Science ®Google Scholar
• Warach S. Tissue viability thresholds in acute stroke: the 4-factor model. Stroke32(11), 2460–2461 (2001).
   PubMedGoogle Scholar
• Campbell BC, Purushotham A, Christensen S et al. The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J. Cereb. Blood Flow Metab.32(1), 50–56 (2012).
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke34(2), 575–583 (2003).
   PubMed Web of Science ®Google Scholar
• Lansberg MG, Lee J, Christensen S et al. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Stroke42(6), 1608–1614 (2011).
   PubMed Web of Science ®Google Scholar
• Campbell BC, Christensen S, Foster SJ et al. Visual assessment of perfusion-diffusion mismatch is inadequate to select patients for thrombolysis. Cerebrovasc. Dis.29(6), 592–596 (2010).
   PubMed Web of Science ®Google Scholar
• Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood–brain barrier disruption in human focal brain ischemia. Ann. Neurol.56(4), 468–477 (2004).
   PubMed Web of Science ®Google Scholar
• Fiehler J, Albers GW, Boulanger JM et al. Bleeding risk analysis in stroke imaging before thrombolysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke38(10), 2738–2744 (2007).
   PubMed Web of Science ®Google Scholar
• Singer OC, Humpich MC, Fiehler J et al. Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann. Neurol.63(1), 52–60 (2008).
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Jansen O, Fiebach JB et al. Feasibility and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. AJNR Am. J. Neuroradiol.21(7), 1184–1189 (2000).
   PubMed Web of Science ®Google Scholar
• Buckley BT, Wainwright A, Meagher T, Briley D. Audit of a policy of magnetic resonance imaging with diffusion-weighted imaging as first-line neuroimaging for in-patients with clinically suspected acute stroke. Clin. Radiol.58(3), 234–237 (2003).
   PubMed Web of Science ®Google Scholar
• Kohrmann M, Juttler E, Fiebach JB et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol.5(8), 661–667 (2006).
   PubMedGoogle Scholar
• Fiebach JB, Schellinger PD, Jansen O et al. CT and diffusion-weighted MR-Imaging in randomized order: DWI results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke33(9), 2206–2210 (2002).
   PubMed Web of Science ®Google Scholar
• Chalela JA, Kidwell C, Nentwich L et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet369(9558), 293–398 (2007).
   PubMed Web of Science ®Google Scholar
• Albers GW, Thijs VN, Wechsler L et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann. Neurol.60(5), 508–517 (2006).
   PubMed Web of Science ®Google Scholar
• Thomalla G, Schwark C, Sobesky J et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in mri-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke37(3), 852–858 (2006).
   PubMed Web of Science ®Google Scholar
• Davis SM, Donnan GA, Parsons MW et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol.7(4), 299–309 (2008).
   PubMed Web of Science ®Google Scholar
• Nagakane Y, Christensen S, Brekenfeld C et al. EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke42(1), 59–64 (2011).
   PubMedGoogle Scholar
• Mlynash M, Lansberg MG, De Silva DA et al. Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke42(5), 1270–1275 (2011).
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Eyding D, Albers GW et al. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke37(5), 1227–1231 (2006).
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke36(1), 66–73 (2005).
   PubMed Web of Science ®Google Scholar
• Hacke W, Furlan AJ, Al-Rawi Y et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol.8(2), 141–150 (2009).
   PubMed Web of Science ®Google Scholar
• Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA282(21), 2003–2011 (1999).
   PubMed Web of Science ®Google Scholar
• Lewandowski CA, Frankel M, Tomsick TA et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: emergency Management of Stroke (EMS) bridging trial. Stroke30(12), 2598–2605 (1999).
   PubMed Web of Science ®Google Scholar
• The IMS 2 Investigators. The second interventional management of stroke study. Presented at: International Stroke Conference. Kissimmee, FL, USA, 16–18 February 2006.
   Google Scholar
• The IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke38(7), 2127–2135 (2007).
   PubMed Web of Science ®Google Scholar
• Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am. J. Neuroradiol.27(6), 1177–1182 (2006).
   PubMed Web of Science ®Google Scholar
• Smith WS, Sung G, Starkman S et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke. Results of the MERCI trial. Stroke36(7), 1432–1440 (2005).
   PubMed Web of Science ®Google Scholar
• Nogueira RG, Liebeskind DS, Sung G, Duckwiler G, Smith WS. Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials. Stroke40(12), 3777–3783 (2009).
   PubMed Web of Science ®Google Scholar
• Struffert T, Kohrmann M, Engelhorn T et al. Penumbra Stroke System as an ‘add-on’ for the treatment of large vessel occlusive disease following thrombolysis: first results. Eur. Radiol.19(9), 2286–2293 (2009).
   PubMedGoogle Scholar
• Bose A, Henkes H, Alfke K et al. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am. J. Neuroradiol.29(7), 1409–1413 (2008).
   PubMed Web of Science ®Google Scholar
• Miteff F, Faulder KC, Goh AC, Steinfort BS, Sue C, Harrington TJ. Mechanical thrombectomy with a self-expanding retrievable intracranial stent (Solitaire AB): experience in 26 patients with acute cerebral artery occlusion. AJNR Am. J. Neuroradiol.32(6), 1078–1081 (2011).
   PubMed Web of Science ®Google Scholar
• Taschner CA, Treier M, Schumacher M, Berlis A, Weber J, Niesen W. Mechanical thrombectomy with the Penumbra recanalization device in acute ischemic stroke. J. Neuroradiol.38(1), 47–52 (2011).
   PubMedGoogle Scholar
• Baker WL, Colby JA, Tongbram V et al. Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. Ann. Intern. Med.154(4), 243–252 (2011).
   PubMedGoogle Scholar
• Benmira S, Banda ZK, Bhattacharya V. The start of a new era for stroke treatment: mechanical thrombectomy devices. Curr. Neurovasc. Res.8(1), 75–85 (2011).
   PubMedGoogle Scholar
• Rohde S, Haehnel S, Herweh C et al. Mechanical thrombectomy in acute embolic stroke: preliminary results with the revive device. Stroke42, 2954–2956 (2011).
   PubMedGoogle Scholar
• Stampfl S, Hartmann M, Ringleb PA, Haehnel S, Bendszus M, Rohde S. Stent placement for flow restoration in acute ischemic stroke: a single-center experience with the solitaire stent system. AJNR Am. J. Neuroradiol.32(7), 1245–1248 (2011).
   PubMedGoogle Scholar
• Jovin TG, Liebeskind DS, Gupta R et al. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. Stroke42(8), 2206–2211 (2011).
   PubMed Web of Science ®Google Scholar
• Nguyen TN, Babikian VL, Romero R et al. Intra-arterial treatment methods in acute stroke therapy. Front. Neurol.2, 9 (2011).
   PubMedGoogle Scholar
• Gupta R, Tayal AH, Levy EI et al. Intra-arterial thrombolysis or stent placement during endovascular treatment for acute ischemic stroke leads to the highest recanalization rate: results of a multicenter retrospective study. Neurosurgery68(6), 1618–1623 (2011).
   PubMedGoogle Scholar
• Mandava P, Kent TA. A method to determine stroke trial success using multidimensional pooled control functions. Stroke40, 1803–1810 (2009).
   PubMedGoogle Scholar
• Khatri P, Hill MD, Palesch YY et al. Methodology of the Interventional Management of Stroke III Trial. Int. J. Stroke3(2), 130–137 (2008).
   PubMed Web of Science ®Google Scholar
• Eckert B, Koch C, Thomalla G et al. Aggressive therapy with intravenous abciximab and intra-arterial rt-PA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study. Stroke36(6), 1160–1165 (2005).
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Hacke W. Recanalization devices should be restricted to clinical trials – Pro (kind of). Stroke41(1), 191–193 (2010).
   PubMedGoogle Scholar
• Coutts SB, Goyal M. When recanalization does not improve clinical outcomes. Stroke40(8), 2661 (2009).
   PubMedGoogle Scholar
• Diener HC, Lees KR, Lyden P et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke39(6), 1751–1758 (2008).
   PubMed Web of Science ®Google Scholar
• Koziol JA, Feng AC. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke37(10), 2644–2647 (2006).
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Weissenborn K, Prange H et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke40(12), e647–e656 (2009).
   PubMed Web of Science ®Google Scholar
• Warach S, Hacke W, Hsu C, Luby M, Sullivan M, Noonan T. Effect of MaxiPost on ischemic lesions in patients with acute stroke: the POST-010 MRI Substudy. Stroke33, 383 (2002).
   Google Scholar
• Warach S, Pettigrew LC, Dashe JF et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann. Neurol.48(5), 713–722 (2000).
   PubMed Web of Science ®Google Scholar
• Warach S, Sabounjian LA. ECCO 2000 study of citicoline for treatment of acute ischemic stroke: effects on infarct volumes measured by MRI. Stroke31(1), 42 (2000).
   Google Scholar
• Clark WM. Efficacy of citicoline as an acute stroke treatment. Expert Opin. Pharmacother.10(5), 839–846 (2009).
   PubMed Web of Science ®Google Scholar
• Schabitz WR, Laage R, Vogt G et al. AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke41(11), 2545–2551 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenberg G, Marshall LS, Caraco Y. The neuroprotective agent DP-b99 does not interact with s-warfarin in vivo despite significant CYP2C9 inhibition in vitro. Basic Clin. Pharm. Toxicol.108(4), 289–292 (2011).
   PubMedGoogle Scholar
• Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke39(6), 1774–1778 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenberg G, Bornstein N, Diener HC, Gorelick PB, Shuaib A, Lees K. The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal Phase III study. Int. J. Stroke6(4), 362–367 (2011).
   PubMed Web of Science ®Google Scholar
• Shuaib A, Bornstein NM, Diener HC et al. Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial. Stroke42(6), 1680–1690 (2011).
   PubMed Web of Science ®Google Scholar
• Liebeskind DS. Aortic occlusion for cerebral ischemia: from theory to practice. Curr. Cardiol. Rep.10(1), 31–36 (2008).
   PubMedGoogle Scholar
• Hammer M, Jovin T, Wahr JA, Heiss WD. Partial occlusion of the descending aorta increases cerebral blood flow in a nonstroke porcine model. Cerebrovasc. Dis.28(4), 406–410 (2009).
   PubMedGoogle Scholar
• Emery DJ, Schellinger PD, Selchen D et al. Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. Stroke42(4), 1135–1137 (2011).
   PubMedGoogle Scholar
• Khurana D, Kaul S, Bornstein NM. Implant for augmentation of cerebral blood flow trial 1: a pilot study evaluating the safety and effectiveness of the ischaemic stroke system for treatment of acute ischaemic stroke. Int. J. Stroke4(6), 480–485 (2009).
   PubMedGoogle Scholar
• Lampl Y, Zivin JA, Fisher M et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke38(6), 1843–1849 (2007).
   PubMed Web of Science ®Google Scholar
• Zivin JA, Albers GW, Bornstein N et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke40(4), 1359–1364 (2009).
   PubMed Web of Science ®Google Scholar